North America Computed Tomography (CT) Market Size

North America Computed Tomography (CT) Market Analysis

The North America Computed Tomography Market size is estimated at USD 2.87 billion in 2024, and is expected to reach USD 3.85 billion by 2029, growing at a CAGR of 5.97% during the forecast period (2024-2029).

The studied market was impacted by the pandemic. Despite the fact that the pandemic has had an impact on elective cases that call for imaging, patients with COVID-19 have seen an upsurge in demand for CT scans. According to a June 2020 paper titled "Chest CT characteristics and their relevance in COVID-19," CT imaging was a crucial auxiliary tool in the diagnosis and subsequent treatment of COVID-19 patients. In the RT-PCR assay, CT can reduce the possibility of false-negative results. The country will experience an upsurge in demand for CT scans during COVID-19 as a result of these findings. The Society of Thoracic Radiology, the American College of Radiology, and the Radiological Society of North America provided additional guidance for the use of plain chest radiography and CT imaging for patients suspected to have COVID-19, according to an article titled "The Usefulness of Chest CT Imaging in Patients with Suspected or Diagnosed COVID-19" published in the Chest Journal in April 2021. The signs were deemed nonspecific, and normal CT imaging results did not completely rule out the infection, hence these guidelines advise against using chest CT imaging routinely to diagnose COVID-19, affecting the country's healthcare system in the process. COVID-19 has impacted the computed tomography market as there were distribution channel disruptions for the majority of radiopharmaceuticals, delays in clinical studies, postponement of various surgeries and imaging procedures, an increase in teleradiology, and several staff-related limitations.

The major factors for the growth of the North American computed tomography (CT) market include the rising geriatric population and increase in the incidences of chronic diseases, increase in the shift of medical care toward image-guided interventions, and technological advancements. The prevalence of diseases like cardiovascular diseases has increased significantly in Canada. For instance, according to a July 2020 article appearing in the Canadian Journal of Cardiology, there have been increases in congenital heart disease (7.2 %), acquired valvular heart disease (31.1%), and vascular cognitive impairment (23.4 %) in the Canadian population over the past ten years. The high burden of cardiovascular diseases is expected to boost the demand for computed tomography equipment for diagnosis leading to the segment's growth. Similarly, according to the Alzheimer Society of Canada 2021, over 500,000 Canadians lived with dementia. By 2030, this number is expected to rise to 912,000. Thus, increasing prevalence of disease are expected to increase market growth.

Furthermore, technological advancement is another factor in market growth. For instance, the United States Food and Drug Administration approved a significant technological advancement for the Siemens NAEOTOM Alpha computed tomography imaging device in September 2021. This device uses the emerging CT technology of photon-counting detectors that can measure each individual X-ray that passes through a patient's body, as opposed to current systems that use detectors that measure the total energy contained in many X-rays at once. By doing this, it is possible to gather more specific information about the patient and use it to produce images that contain fewer details that are useless for inspection and analysis. During the anticipated time, the market in the region will grow as a result of such technological innovation in the relevant market. Thus, the abovementioned factors are expected to increase market growth.

However, the lack of adequate reimbursement and stringent regulatory framework are expected to hinder the market growth.